A Phase I/IIa Study of AZD8205 given alone or in Combination with Anticancer Drugs, in Participants with Advanced or Metastatic Solid Malignancies

Trial Identifier: D6900C00001
Sponsor: AstraZeneca
NCTID:: NCT05123482
Start Date: October 2021
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Breast Cancer; Endometriosis; Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, VIC 3000
AU Nedlands, AU, 6009
CA, BC Vancouver, BC, CA, V5Z 4E6
CA, QC Montreal, QC, CA, H4A 3J1
CN Beijing, CN, 100142
CN Changsha, CN, 410013
CN Guangzhou, CN, 510060
ES Barcelona, ES, 8035
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Madrid, ES, 28027
ES Málaga, ES, 29010
ES Pamplona, ES, 31008
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
KR seoul, KR, 06351
KR Seoul, KR, 03080
KR Seoul, KR, 05505
KR Seoul, KR, 03722
US, CA Duarte, CA, US, 91010
US, CA Irvine, CA, US, 92618
US, CA Santa Monica, CA, US, 90404
US, FL Sarasota, FL, US, 34232
US, MD Baltimore, MD, US, 21231
US, MO Saint Louis, MO, US, 63110
US, NM Albuquerque, NM, US, 87109
US, NY Commack, NY, US, 11725
US, TX Houston, TX, US, 77030